Cost Savings from Administering Cancer Drugs in Alternative Settings

This report examines the financial implications of administering cancer drugs in lower-cost settings compared to traditional hospital outpatient departments. It outlines how high-cost specialty drugs account for over $100 billion in annual spending for commercially insured individuals, with hospital outpatient departments receiving the highest payments. The report details the advantages of administering these drugs in independent physician offices, patients' homes, and independent infusion centers, which can reduce costs by 32% to 39% per patient. It presents data indicating that the share of cancer patients receiving treatment in hospital settings increased to 60% from 2018 to 2024, while other conditions saw a decline. The report also discusses the impact of the 340B Drug Pricing Program on drug spending growth and highlights potential annual savings of $12 billion if the administration of cancer drugs shifts from hospital settings to lower-cost alternatives. Methodology includes an analysis of claims data for UnitedHealthcare members to estimate costs and utilization rates.